Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: L-Dopa Clear all
Completed Not applicable Interventional

Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease

NCT00552474
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders
Interventions
Libra Deep Brain Stimulation System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
15
States / cities
Loma Linda, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

NCT02633007
View directory record Official record
Conditions
Asthma
Interventions
CVT-301 (levodopa inhalation powder), Carbidopa, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

NCT01770145
View directory record Official record
Conditions
Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility, Delayed Levodopa Onset
Interventions
APOKYN, L-dopa, Trimethobenzamide
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491529
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders, Anti-Dyskinesia Agents
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Sunnyvale, California • Englewood, Colorado • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects

NCT03581305
View directory record Official record
Conditions
Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
Interventions
18F-FDOPA, 11C-DASB
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

NCT01283594
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

DTA (Dopaminergic Therapy for Anhedonia) Study

NCT04723147
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Results available

Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome

NCT00829439
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Levodopa/Carbidopa (4:1)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Sep 1, 2026, 10:42 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

NCT02696512
View directory record Official record
Conditions
Brain Injury
Interventions
Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care
Drug · Device · Dietary Supplement + 1 more
Lead sponsor
International Brain Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 1, 2026, 10:42 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Histaminergic Basis of Fatigue in Multiple Sclerosis

NCT04764383
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
L-Histidine, Placebo, Lodosyn
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Modulating Glucose Tolerance With Dietary Tyrosine

NCT03872557
View directory record Official record
Conditions
Glucose Tolerance
Interventions
Tyrosine (TYR) Supplementation
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

NCT03266965
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Carbidopa, L-Histidine
Drug · Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

NCT00314288
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Sarizotan HCl
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
30 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
17
States / cities
Fountain Valley, California • Sunnyvale, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Early Phase 1 Interventional

A Targeted Amino Acid Supplement for People With Parkinson's Disease

NCT06954662
View directory record Official record
Conditions
Parkinson Disease, Idiopathic
Interventions
Amino acid supplement, Whey Protein Supplement, Isonitrogenous Placebo Supplement
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
55 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

NCT06234995
View directory record Official record
Conditions
Parkinson Disease
Interventions
Levodopa, Clinical DBS Setting, Sham DBS, DBS Setting Maximizing Prefrontal Activation, DBS Setting Minimizing Prefrontal Activation
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
45 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 1 Interventional

Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma

NCT02176720
View directory record Official record
Conditions
Glioma, Glioblastoma, Glioblastoma Multiforme
Interventions
FDOPA PET
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 1, 2026, 10:42 AM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

NCT02812147
View directory record Official record
Conditions
Parkinson Disease
Interventions
L-DOPS, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Vigor and the LDR in Parkinson Disease

NCT04821830
View directory record Official record
Conditions
Parkinson Disease
Interventions
carbidopa/levodopa, as prescribed by treating physician
Drug
Lead sponsor
University of Michigan
Other
Eligibility
45 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 1, 2026, 10:42 AM EDT
Withdrawn Phase 2 Interventional

A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

NCT02873351
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
carbidopa-levodopa 25-100 mg, placebo for carbidopa-levodopa 25-100 mg
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Active, not recruiting Phase 2 Interventional

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

NCT05781321
View directory record Official record
Conditions
Glioblastoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide, Biospecimen Collection
Radiation · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional

VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

NCT03562494
View directory record Official record
Conditions
Parkinson's Disease
Interventions
VY-AADC02, Sham (Placebo) Surgery
Biological · Other
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Irvine, California • Sacramento, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD

NCT03243552
View directory record Official record
Conditions
ASD
Interventions
L-DOPA versus Placebo, Social Skills Training
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 30 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 1, 2026, 10:42 AM EDT
Completed No phase listed Observational

Biomarkers of Risk of Parkinson Disease

NCT00775853
View directory record Official record
Conditions
Parkinson Disease, Autonomic Nervous System Diseases, Pure Autonomic Failure
Interventions
6-[18F]Fluorodopamine, 6-[18F]Fluorodopa, 13N-Ammonia
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 1, 2026, 10:42 AM EDT